Help Navigate Common Hurdles With GLP-1 Agonists

February 2024

Questions are rolling in about GLP-1 agonists...dulaglutide (Trulicity), liraglutide (Victoza), semaglutide (Ozempic, etc), etc.

It’s partly because these meds are a first-line option for type 2 diabetes with compelling indications...such as CV or kidney disease.

Plus semaglutide or the dual agonist tirzepatide (Zepbound, etc) seem to be the most effective meds for managing overweight or obesity.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: MD includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote